Trial Profile
A Phase 2 Study of BPM31510 (Ubidecarenone, USP) Nanosuspension Injection Administered Intravenously With Gemcitabine as 2nd/3rdline Therapy in Advanced Pancreatic Cancer Patients
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 01 Mar 2024
Price :
$35
*
At a glance
- Drugs Gemcitabine (Primary) ; Ubidecarenone (Primary)
- Indications Adenocarcinoma; Pancreatic cancer
- Focus Therapeutic Use
- Sponsors Berg Pharma
- 20 Jan 2024 Results presented at the 2024 Gastrointestinal Cancers Symposium
- 18 Jan 2024 Results presented in BPGbio media release.
- 18 Jan 2024 According to BPGbio media release, the company will announce new data at the annual ASCO Gastrointestinal Cancers Symposium, being held January 18-20, 2024, in San Francisco, Calif.